본문으로 건너뛰기

Yahoo Finance 등 미국 증권 원문(영문)을 구글 자동번역으로 한국어 표시합니다. 번역은 참고용입니다.

증권

JBT Marel (JBTM) Rides Record Orders Into A Messy Quarter

On August 3, JBT Marel Corporation (NYSE:JBTM) reported second-quarter 2026 results that read as two different companies stapled together. Orders topped $1 billion, pushing the book-to-bill ratio to 1.05x and lifting backlog to $1.54 billion. But net income of $28 million included a $33 million non-cash impairment charge tied to a 2021 acquisition, a reminder […]

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

On August 3, JBT Marel Corporation (NYSE:JBTM) reported second-quarter 2026 results that read as two different companies stapled together. Orders topped $1 billion, pushing the book-to-bill ratio to 1.05x and lifting backlog to $1.54 billion. But net income of $28 million included a $33 million non-cash impairment charge tied to a 2021 acquisition, a reminder that not every dollar in this business is showing up cleanly on the bottom line.

The order book is the headline here. JBT Marel booked $1.03 billion in orders during the quarter, and revenue of $981 million grew 5% year over year, with about 2 percentage points of that coming from foreign exchange translation. Adjusted EBITDA rose to $168 million, up $12 million, and the adjusted EBITDA margin improved 40 basis points to 17.1%. Diluted earnings per share jumped to $0.54 from $0.07 a year earlier, while adjusted EPS climbed to $1.95 from $1.49.

The Protein Solutions segment did the heavy lifting, with revenue up 11% to $467 million and segment adjusted EBITDA margin expanding 350 basis points to 24%. Management also pointed to $60 million in expected in-year cost synergy savings for 2026 and kept its full-year revenue guidance of $3.99 billion to $4.065 billion and adjusted EBITDA margin guidance of 17% to 17.5% unchanged. The company's balance sheet moved in the right direction too, with net debt to trailing twelve-month adjusted EBITDA at 2.47x, and it repurchased about 200,000 shares for $26 million under its $200 million buyback authorization.

The Prepared Food and Beverage Solutions segment told a different story. Revenue there was flat at $514 million despite a 2 percentage point foreign exchange tailwind, and segment adjusted EBITDA margin slipped 70 basis points to 17.5%. The company attributed the shortfall to logistics constraints and productivity inefficiencies as it works through backlog-to-revenue conversion. Layered on top of that operational friction was the $33 million non-cash impairment charge, which the company said was non-recurring but which still dragged GAAP diluted EPS guidance for the full year down to a range of $4.20 to $4.70 and net income margin guidance to 5.5% to 6.0%.

Management also flagged higher inflationary costs as an ongoing headwind it is trying to offset through pricing actions. For the full year, JBT Marel still expects to absorb $167 million in acquisition-related amortization and depreciation, $32 million in M&A-related costs, and $20 million in restructuring costs, on top of the impairment already booked. And at 2.47x, leverage is sitting just below the top of the company's own 2.0x to 2.5x target range, leaving less room to maneuver than the balance sheet headline suggests.

Hedge fund ownership fell from 40 funds to 33 in the most recent quarter, a drop that reads as institutional buyers stepping back rather than piling in. Short interest sits at 9.24% of float, a level that suggests a real bear camp has formed around the stock. JBT Marel trades at a forward P/E of 12.69 as of September 4, a multiple that does not appear to be pricing in much of the growth implied by that swelling backlog. A cheap earnings multiple sitting next to elevated short interest and a shrinking hedge fund count is exactly where the disagreement about this stock lives right now.

JBT Marel's second quarter leaves two threads dangling. Orders and backlog point to a company gathering momentum, and management reiterated its full-year revenue and adjusted EBITDA margin guidance as of August 3, 2026. Yet the Prepared Food and Beverage Solutions segment still has to work through the logistics constraints that held back its results, and leverage sitting just below the top of the target range leaves less cushion than it used to. Whether that backlog converts into clean revenue growth in the back half of 2026 will say more about this story than the headline order numbers already have.

While we acknowledge the potential of JBTM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.

Disclosure: None. Follow Insider Monkey on Google News.

JBT Marel Q2 Earnings Call Highlights MarketBeat • 1mo ago JBTM

Stronger Earnings, Buybacks, Dividend And Guidance Might Change The Case For Investing In JBT Marel (JBTM) Simply Wall St. • 18d ago JBTM

Stronger Earnings, Buybacks, Dividend And Guidance Might Change The Case For Investing In JBT Marel (JBTM)

JBT Marel Corp (JBTM) (Q2 2026) Earnings Call Highlights: Record Orders and Strategic Progress ... GuruFocus.com • 1mo ago JBTM

JBT Marel Corp (JBTM) (Q2 2026) Earnings Call Highlights: Record Orders and Strategic Progress ...

JBT Marel (NYSE:JBTM) Posts Q2 CY2026 Sales In Line With Estimates but Non-GAAP EPS Miss StockStory • 1mo ago JBTM

JBT Marel (NYSE:JBTM) Posts Q2 CY2026 Sales In Line With Estimates but Non-GAAP EPS Miss

JBT Marel’s (NYSE:JBTM) Q1 CY2026: Beats On Revenue, Stock Soars StockStory • 3mo ago JBTM

JBT Marel’s (NYSE:JBTM) Q1 CY2026: Beats On Revenue, Stock Soars

JBT Marel’s Q2 Earnings Call: Our Top 5 Analyst Questions StockStory • 24d ago JBTM

JBT Marel’s Q2 Earnings Call: Our Top 5 Analyst Questions

JBT Marel Q2 Adjusted Earnings, Revenue Rise PREMIUM MT Newswires • 1mo ago JBTM FDS

JBT Marel Q2 Adjusted Earnings, Revenue Rise

Earnings To Watch: JBT Marel Corp (JBTM) Q2 2026 -- GF Value Sees 16% Upside GuruFocus.com • 1mo ago JBTM

Earnings To Watch: JBT Marel Corp (JBTM) Q2 2026 -- GF Value Sees 16% Upside

Earnings To Watch: JBT Marel Corp (JBTM) Q2 2026 -- GF Value Sees 19% Upside GuruFocus.com • 1mo ago JBTM

Earnings To Watch: JBT Marel Corp (JBTM) Q2 2026 -- GF Value Sees 19% Upside

JBT Marel Corp (JBTM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Margin ... GuruFocus.com • 6mo ago JBTM

JBT Marel Corp (JBTM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Margin ...

참고 자료Yahoo Finance

이 기사는 위 자료를 바탕으로 위클리뉴스가 재작성했습니다. 원문은 링크에서 확인하세요.